Literature DB >> 1198127

Spurious polycythemia.

N J Weinreb, C F Shih.   

Abstract

Spurious polycythemia is not a primary disease process. It sometimes may be nothing more than an unusual, but normal, physiologic state. In other instances, however, it is associated with a true abnormality of plasma volume. Although there is probably overlap between these extremes, differentiation of these subclasses may be of prognostic significance. The elevation in hematocrit bears no relation to morbidity, and, because there is no evidence of abnormal erythroid proliferation, reduction of red cell volume via phlebotomy or myelosuppression is inappropriate. Nonhematologic parameters, particularly hypertension, are the major factors of significance in the substantial cardiovascular morbidity in spurious polycythemia, and they demand attentive and aggressive management.

Entities:  

Mesh:

Year:  1975        PMID: 1198127

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  3 in total

1.  Relative erythrocytosis: an approach to the patient.

Authors:  F A Lederle
Journal:  J Gen Intern Med       Date:  1987 Mar-Apr       Impact factor: 5.128

Review 2.  Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.

Authors:  Douglas Tremblay; Abdulraheem Yacoub; Ronald Hoffman
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-26       Impact factor: 3.722

3.  Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis.

Authors:  Shota Kodaira; Jun Ehara; Shigemasa Takamizawa; Shin Ogita; Yasuhiro Norisue; Tatsuya Nakama; Eiji Hiraoka
Journal:  Am J Case Rep       Date:  2021-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.